Simplify Logo

Full-Time

Research Scientist

Biophysics / Molecular Interactions

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$75.2k - $94kAnnually

+ Equity + Bonus + RRSP Contribution + Active Lifestyle Allowance

Senior, Expert

Vancouver, BC, Canada

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Requirements
  • You have a PhD in Biophysics, Biochemistry, or Structural Biology, or a MSc degree plus 5+ years of relevant experience
  • You have demonstrated experience using Carterra, Biacore, and Octet platforms to characterize protein binding kinetics, affinity and epitope
  • You have experience running plate based assays, analyzing large data sets, and interpreting and communicating data in the context of broader project objectives
  • You have impeccable attention to detail with excellent documentation and organizational skills
  • You have effective decision-making and troubleshooting skills, with impeccable attention to detail
  • You have great interpersonal skills with the ability to work collaboratively as a member of cross-functional team
Responsibilities
  • Using biosensor based technologies such as surface plasmon resonance (SPR) or biolayer interferometry (BLI) to rapidly screen through hundreds to thousands of candidate antibodies to identify lead molecules with desired kinetic, affinity and epitope profiles
  • Conducting detailed characterization of the kinetics, affinity, and mechanism of action of lead molecules, including for example, assessing pH-dependent binding, Fc effector function, and other critical properties
  • Evaluating the properties of bispecific antibodies and other multispecific molecules, in support of lead selection and optimization
  • Developing high throughput workflows for antibody kinetic and epitope analysis, and automating these workflows using liquid handlers
  • Working with data scientists, machine learning and software engineers to streamline the capture, curation and analysis of large data sets
  • Collaborating with teammates from discovery biology, protein engineering and other teams to build platforms and processes, as well as analyze, interpret and communicate data
  • Providing protein science and biotherapeutic leadership within multidisciplinary drug discovery teams
  • Mentoring and developing junior scientists within a rapidly growing and dynamic team

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Series A

Total Funding

$393.1M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

2%

1 year growth

0%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.